Molecular Pharmaceutics · 2020 · 19 citations · 40 references
MedicineNuclear MedicineOncologyMolecular ImagingRadionuclide TherapyTherapeutic Nuclear MedicineOncologic Nuclear ImagingProstate Cancer ImagingRadiopharmaceutical TherapyRadiotracer DevelopmentTargeted Imaging AgentsTargeted Radionuclide TherapyProstate Cancer DiagnosisProstate-specific Antigen - Targeted TherapyProstate-specific Membrane Antigen PetProstate-specific Membrane Antigen Positron Emission TomographyProstate-specific Membrane Antigen RadioligandsPsma Targeting LigandsPsma-pet ImagingPsma-targeted Therapy
Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer cells and therefore is an attractive target for prostate cancer diagnosis and radionuclide therapy. Recently, published results from clinical studies using a new PSMA-targeting PET imaging agent, [68Ga]Ga-PSMA-093 ([68Ga]Ga-HBED-CC-O-carboxymethyl-Tyr-CO-NH-Glu), support the development of this agent for the diagnosis of prostate cancer. In this study, the HBED-CC chelating group in PSMA-093 was replaced by stereoselective (R)- or (S)-DOTAGA. This chelating group serves not only for chelating 68Ga but is also amendable for complexing other radioactive metals for radionuclide therapy. The corresponding optically pure (R)- and (S)-[68Ga/177Lu]-DOTAGA derivatives, (R)-[68Ga/177Lu]-13 and (S)-[68Ga/177Lu]-13, were successfully prepared. Comparison of radiolabeling, binding affinity, cell uptake, and biodistribution between the two isomers was performed. Radiolabeling of (R)-[177Lu]Lu-13 and (S)-[177Lu]Lu-13 at 50 °C suggested that rates of complex formation were time-dependent and the formation of (S)-[177Lu]Lu-13 was distinctly faster. The rates of complex formation for the corresponding 68Ga agents were comparable between structural isomers. The natGa and natLu equivalents showed high binding PSMA affinity (IC50 = 24–111 nM), comparable to that of the parent agent, [natGa]Ga-PSMA-093 (IC50 = 34.0 nM). Results of cell uptake and biodistribution studies in PSMA-expressing PC3-PIP tumor-bearing mice appeared to show no difference between the labeled (R)- and (S)-isomers. This is the first time that a pair of [68Ga/177Lu]-(R)- and (S)-DOTAGA isomers of PSMA agents were evaluated. Results of biological studies between the isomers showed no noticeable difference; however, the distinctions on the rate of Lu complex formation should be considered in the development of new 177Lu-DOTAGA-based radionuclide therapy agents in the future.
40
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2020 · 21.4K citations · Full text
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 21K citations · Full text
Martina Weineisen, Margret Schottelius, Jakub Šimeček et al. · Journal of Nuclear Medicine · 2015 · 532 citations · Full text
Medicine, Oncology, Pharmacology +17
Shawn Hillier, Kevin Maresca, F.J. Femia et al. · Cancer Research · 2009 · 318 citations · Full text
Medicine, Oncology, Pharmacology +14
Martina Benešová, Ulrike Bauder‐Wüst, Martin Schäfer et al. · Journal of Medicinal Chemistry · 2016 · 222 citations · Full text
Pharmacy, Oncology, Pharmacology +15